PCM
AMLX icon

Pentwater Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Pentwater Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-30,000
Closed -$880K – 133
2023
Q1 		$880K Sell
30,000
-5,000
-14% -$174K 0.01% 122
2022
Q4 		$1.29M Buy
+35,000
New +$1.24M 0.02% 94

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Pentwater Capital Management's AMLX Position: Q2 2023 in Review

Pentwater Capital Management sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2023, closing a stake of 30,000 shares — an estimated $880K sold.

Pentwater Capital Management first reported a position in AMLX in Q4 2022 and held it in 2 quarters. The position peaked at $1.29M in Q4 2022. 154 funds tracked by Wall St. Rank hold AMLX as of Q2 2023.

  • Pentwater Capital Management reported no remaining Amylyx Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Pentwater Capital Management sold 30,000 Amylyx Pharmaceuticals shares in Q2 2023, an estimated $880K.
  • Pentwater Capital Management first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Pentwater Capital Management's Amylyx Pharmaceuticals position peaked at $1.29M in Q4 2022.
  • 154 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2023.

Based on Pentwater Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.